Skip to main content
Erschienen in: Clinical & Experimental Metastasis 7/2013

01.10.2013 | Research Paper

SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis

verfasst von: Susan Specht, Kumiko Isse, Isao Nozaki, John G. Lunz III, Anthony J. Demetris

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Cholangiocarcinoma morbidity and mortality is attributable to local invasiveness and regional lymph node and distant organ metastasis. Cholangiocarcinoma progression follows a series of sequential events that resemble wound healing reactions: local invasion resembles the epithelial migration phase involving epithelial–mesenchymal transition (EMT); colonization at distant sites resembles epithelial restitution seen during the reverse process, mesenchymal–epithelial transition (MET). In this study we compare the in vivo local and metastatic growth potential of cholangiocarcinoma cell lines with respect to expression of a novel pSTAT3-dependent, biliary epithelial cell wound healing protein, small proline-rich protein 2A (SPRR2A). SPRR2A has been associated with local aggressiveness, but decreased metastatic capabilities in other cancers. Stable SPRR2A transfection into two cholangiocarcinoma cell lines (SG231 and HuCCT-1), previously shown by us to induce permanent EMT, resulted in local aggressiveness but an inability to form metastases. In contrast, SPRR2A-negative epithelial control cells showed relatively poor local aggressiveness, but readily formed metastatic tumors. Post-intrasplenic injection cell tracking showed that: (a) mesenchymal (SPRR2A+) cells were not trapped in the liver, but were rapidly cleared through mesenteric lymph nodes and did not form metastases; whereas (b) epithelial (SPRR2A−) controls were primarily entrapped within MUC-1-associated liver “micro-infarcts” that later evolved into metastatic colonies. SPRR2A-associated tumor behavior was mimicked by MUC1 shRNA, which induced EMT and, like SPRR2A+ cells, showed reduced metastatic capabilities. Cholangiocarcinoma local invasion involves EMT processes, whereas MET and MUC1 expression promote metastasis. A better understanding of disease progression should help target treatment for this deadly neoplasm.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nozaki I, Lunz JG 3rd, Specht S et al (2005) Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation. Lab Invest 85(1):109–123PubMedCrossRef Nozaki I, Lunz JG 3rd, Specht S et al (2005) Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation. Lab Invest 85(1):109–123PubMedCrossRef
2.
Zurück zum Zitat Demetris AJ, Lunz JG 3rd, Specht S et al (2006) Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. World J Gastroenterol 12(22):3512–3522PubMed Demetris AJ, Lunz JG 3rd, Specht S et al (2006) Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. World J Gastroenterol 12(22):3512–3522PubMed
3.
Zurück zum Zitat Demetris AJ, Specht S, Nozaki I et al (2008) Small proline-rich proteins (SPRR) function as SH3 domain ligands, increase resistance to injury and are associated with epithelial-mesenchymal transition (EMT) in cholangiocytes. J Hepatol 48(2):276–288PubMedCrossRef Demetris AJ, Specht S, Nozaki I et al (2008) Small proline-rich proteins (SPRR) function as SH3 domain ligands, increase resistance to injury and are associated with epithelial-mesenchymal transition (EMT) in cholangiocytes. J Hepatol 48(2):276–288PubMedCrossRef
4.
Zurück zum Zitat Cabral A, Voskamp P, Cleton-Jansen AM et al (2001) Structural organization and regulation of the small proline-rich family of cornified envelope precursors suggest a role in adaptive barrier function. J Biol Chem 276(22):19231–19237PubMedCrossRef Cabral A, Voskamp P, Cleton-Jansen AM et al (2001) Structural organization and regulation of the small proline-rich family of cornified envelope precursors suggest a role in adaptive barrier function. J Biol Chem 276(22):19231–19237PubMedCrossRef
5.
Zurück zum Zitat Vermeij WP, Alia A, Backendorf C (2011) ROS quenching potential of the epidermal cornified cell envelope. J Invest Dermatol 131(7):1435–1441PubMedCrossRef Vermeij WP, Alia A, Backendorf C (2011) ROS quenching potential of the epidermal cornified cell envelope. J Invest Dermatol 131(7):1435–1441PubMedCrossRef
6.
Zurück zum Zitat Vermeij WP, Backendorf C (2010) Skin cornification proteins provide global link between ROS detoxification and cell migration during wound healing. PLoS ONE 5(8):e11957PubMedCrossRef Vermeij WP, Backendorf C (2010) Skin cornification proteins provide global link between ROS detoxification and cell migration during wound healing. PLoS ONE 5(8):e11957PubMedCrossRef
7.
Zurück zum Zitat Vermeij WP, Florea BI, Isenia S et al (2012) Proteomic identification of in vivo interactors reveals novel function of skin cornification proteins. J Proteome Res. doi:10.1021/pr300310b PubMed Vermeij WP, Florea BI, Isenia S et al (2012) Proteomic identification of in vivo interactors reveals novel function of skin cornification proteins. J Proteome Res. doi:10.​1021/​pr300310b PubMed
8.
Zurück zum Zitat Schafer M, Werner S (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 9(8):628–638PubMedCrossRef Schafer M, Werner S (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 9(8):628–638PubMedCrossRef
9.
Zurück zum Zitat Yao D, Dai C, Peng S (2011) Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 9(12):1608–1620PubMedCrossRef Yao D, Dai C, Peng S (2011) Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 9(12):1608–1620PubMedCrossRef
10.
Zurück zum Zitat Sano S, Itami S, Takeda K et al (1999) Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18(17):4657–4668PubMedCrossRef Sano S, Itami S, Takeda K et al (1999) Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18(17):4657–4668PubMedCrossRef
11.
Zurück zum Zitat Chiarle R, Simmons WJ, Cai H et al (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11(6):623–629PubMedCrossRef Chiarle R, Simmons WJ, Cai H et al (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11(6):623–629PubMedCrossRef
12.
Zurück zum Zitat Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10):740–749PubMedCrossRef Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10):740–749PubMedCrossRef
13.
Zurück zum Zitat Lassmann S, Schuster I, Walch A et al (2007) STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol 60(2):173–179PubMedCrossRef Lassmann S, Schuster I, Walch A et al (2007) STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol 60(2):173–179PubMedCrossRef
14.
Zurück zum Zitat Masuda M, Suzui M, Yasumatu R et al (2002) Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62(12):3351–3355PubMed Masuda M, Suzui M, Yasumatu R et al (2002) Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62(12):3351–3355PubMed
15.
Zurück zum Zitat Niu G, Wright KL, Huang M et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000–2008PubMedCrossRef Niu G, Wright KL, Huang M et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000–2008PubMedCrossRef
16.
Zurück zum Zitat Li L, Shaw PE (2004) A STAT3 dimer formed by inter-chain disulphide bridging during oxidative stress. Biochem Biophys Res Commun 322(3):1005–1011PubMedCrossRef Li L, Shaw PE (2004) A STAT3 dimer formed by inter-chain disulphide bridging during oxidative stress. Biochem Biophys Res Commun 322(3):1005–1011PubMedCrossRef
17.
Zurück zum Zitat Waris G, Ahsan H (2006) Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 5:14PubMedCrossRef Waris G, Ahsan H (2006) Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 5:14PubMedCrossRef
18.
Zurück zum Zitat auf dem Keller U, Kumin A, Braun S et al (2006) Reactive oxygen species and their detoxification in healing skin wounds. J Investig Dermatol Symp Proc 11(1):106–111PubMedCrossRef auf dem Keller U, Kumin A, Braun S et al (2006) Reactive oxygen species and their detoxification in healing skin wounds. J Investig Dermatol Symp Proc 11(1):106–111PubMedCrossRef
19.
Zurück zum Zitat Li C, Jackson RM (2002) Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 282(2):C227–C241PubMedCrossRef Li C, Jackson RM (2002) Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 282(2):C227–C241PubMedCrossRef
20.
Zurück zum Zitat Terui K, Enosawa S, Haga S et al (2004) Stat3 confers resistance against hypoxia/reoxygenation-induced oxidative injury in hepatocytes through upregulation of Mn-SOD. J Hepatol 41(6):957–965PubMedCrossRef Terui K, Enosawa S, Haga S et al (2004) Stat3 confers resistance against hypoxia/reoxygenation-induced oxidative injury in hepatocytes through upregulation of Mn-SOD. J Hepatol 41(6):957–965PubMedCrossRef
21.
Zurück zum Zitat Mizuguchi Y, Specht S, Lunz JG 3rd et al (2012) Cooperation of p300 and PCAF in the control of microRNA 200c/141 transcription and epithelial characteristics. PLoS One 7(2):e32449PubMedCrossRef Mizuguchi Y, Specht S, Lunz JG 3rd et al (2012) Cooperation of p300 and PCAF in the control of microRNA 200c/141 transcription and epithelial characteristics. PLoS One 7(2):e32449PubMedCrossRef
22.
Zurück zum Zitat Mizuguchi Y, Specht S, Lunz JG 3rd et al (2012) SPRR2a enhances p53 deacetylation through HDAC1 and down regulates p21 promoter activity. BMC Mol Biol 13(1):20PubMedCrossRef Mizuguchi Y, Specht S, Lunz JG 3rd et al (2012) SPRR2a enhances p53 deacetylation through HDAC1 and down regulates p21 promoter activity. BMC Mol Biol 13(1):20PubMedCrossRef
23.
Zurück zum Zitat Kim JC, Yu JH, Cho YK et al (2012) Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer. Breast Cancer Res Treat 133(3):909–916PubMedCrossRef Kim JC, Yu JH, Cho YK et al (2012) Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer. Breast Cancer Res Treat 133(3):909–916PubMedCrossRef
24.
Zurück zum Zitat Hippo Y, Yashiro M, Ishii M et al (2001) Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 61(3):889–895PubMed Hippo Y, Yashiro M, Ishii M et al (2001) Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 61(3):889–895PubMed
25.
Zurück zum Zitat Chen BS, Wang MR, Cai Y et al (2000) Decreased expression of SPRR3 in Chinese human oesophageal cancer. Carcinogenesis 21(12):2147–2150PubMedCrossRef Chen BS, Wang MR, Cai Y et al (2000) Decreased expression of SPRR3 in Chinese human oesophageal cancer. Carcinogenesis 21(12):2147–2150PubMedCrossRef
26.
Zurück zum Zitat Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24(3):148–154PubMedCrossRef Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24(3):148–154PubMedCrossRef
27.
Zurück zum Zitat Yokomuro S, Tsuji H, Lunz JG 3rd et al (2000) Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 32(1):26–35PubMedCrossRef Yokomuro S, Tsuji H, Lunz JG 3rd et al (2000) Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 32(1):26–35PubMedCrossRef
28.
Zurück zum Zitat Han C, Leng J, Demetris AJ et al (2004) Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 64(4):1369–1376PubMedCrossRef Han C, Leng J, Demetris AJ et al (2004) Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 64(4):1369–1376PubMedCrossRef
29.
Zurück zum Zitat Walker JA, Kilroy GE, Xing J et al (2003) Human DNA quantitation using Alu element-based polymerase chain reaction. Anal Biochem 315(1):122–128PubMedCrossRef Walker JA, Kilroy GE, Xing J et al (2003) Human DNA quantitation using Alu element-based polymerase chain reaction. Anal Biochem 315(1):122–128PubMedCrossRef
30.
Zurück zum Zitat Suh KS, Roh HR, Koh YT et al (2000) Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 31(1):12–17PubMedCrossRef Suh KS, Roh HR, Koh YT et al (2000) Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 31(1):12–17PubMedCrossRef
31.
Zurück zum Zitat Giavazzi R, Jessup JM, Campbell DE et al (1986) Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst 77(6):1303–1308PubMed Giavazzi R, Jessup JM, Campbell DE et al (1986) Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst 77(6):1303–1308PubMed
32.
Zurück zum Zitat Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45–60PubMedCrossRef Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45–60PubMedCrossRef
33.
Zurück zum Zitat Varki A (2007) Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 110(6):1723–1729PubMedCrossRef Varki A (2007) Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 110(6):1723–1729PubMedCrossRef
34.
Zurück zum Zitat Guaita S, Puig I, Franci C et al (2002) Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 277(42):39209–39216PubMedCrossRef Guaita S, Puig I, Franci C et al (2002) Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 277(42):39209–39216PubMedCrossRef
35.
Zurück zum Zitat Andrianifahanana M, Moniaux N, Batra SK (2006) Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 1765(2):189–222PubMed Andrianifahanana M, Moniaux N, Batra SK (2006) Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 1765(2):189–222PubMed
36.
Zurück zum Zitat Gao J, McConnell MJ, Yu B et al (2009) MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 35(2):337–345PubMed Gao J, McConnell MJ, Yu B et al (2009) MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 35(2):337–345PubMed
37.
Zurück zum Zitat Sachdeva M, Mo YY (2010) MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70(1):378–387PubMedCrossRef Sachdeva M, Mo YY (2010) MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70(1):378–387PubMedCrossRef
38.
Zurück zum Zitat Thiery JP, Acloque H, Huang RY et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890PubMedCrossRef Thiery JP, Acloque H, Huang RY et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890PubMedCrossRef
39.
Zurück zum Zitat Barriere G, Tartary M, Rigaud M (2012) Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol 2012:382010PubMed Barriere G, Tartary M, Rigaud M (2012) Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol 2012:382010PubMed
40.
Zurück zum Zitat Chaffer CL, Brennan JP, Slavin JL et al (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66(23):11271–11278PubMedCrossRef Chaffer CL, Brennan JP, Slavin JL et al (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66(23):11271–11278PubMedCrossRef
41.
Zurück zum Zitat Tsuji T, Ibaragi S, Hu GF (2009) Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69(18):7135–7139PubMedCrossRef Tsuji T, Ibaragi S, Hu GF (2009) Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69(18):7135–7139PubMedCrossRef
42.
Zurück zum Zitat Klerk CP, Smorenburg SM, Otten HM et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23(10):2130–2135PubMedCrossRef Klerk CP, Smorenburg SM, Otten HM et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23(10):2130–2135PubMedCrossRef
43.
Zurück zum Zitat Moggs JG, Tinwell H, Spurway T et al (2004) Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ Health Perspect 112(16):1589–1606PubMedCrossRef Moggs JG, Tinwell H, Spurway T et al (2004) Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ Health Perspect 112(16):1589–1606PubMedCrossRef
44.
Zurück zum Zitat Gaemers IC, Vos HL, Volders HH et al (2001) A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 276(9):6191–6199PubMedCrossRef Gaemers IC, Vos HL, Volders HH et al (2001) A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 276(9):6191–6199PubMedCrossRef
45.
Zurück zum Zitat Horn G, Gaziel A, Wreschner DH et al (2009) ERK and PI3 K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res 315(8):1490–1504PubMedCrossRef Horn G, Gaziel A, Wreschner DH et al (2009) ERK and PI3 K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res 315(8):1490–1504PubMedCrossRef
46.
Zurück zum Zitat Roy LD, Sahraei M, Subramani DB et al (2011) MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30(12):1449–1459PubMedCrossRef Roy LD, Sahraei M, Subramani DB et al (2011) MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30(12):1449–1459PubMedCrossRef
47.
Zurück zum Zitat Bozkaya G, Korhan P, Cokakli M et al (2012) Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer 11(1):64PubMedCrossRef Bozkaya G, Korhan P, Cokakli M et al (2012) Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer 11(1):64PubMedCrossRef
Metadaten
Titel
SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis
verfasst von
Susan Specht
Kumiko Isse
Isao Nozaki
John G. Lunz III
Anthony J. Demetris
Publikationsdatum
01.10.2013
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 7/2013
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-013-9589-2

Weitere Artikel der Ausgabe 7/2013

Clinical & Experimental Metastasis 7/2013 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.